AzTrials
AzTrials

Wolff-Parkinson-White SyndromeRASAPNCT03301935

Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation

An observational study of Wolff-Parkinson-White Syndrome, run by Karolinska University Hospital at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Read more about this study

Who is it for?
Any age
Conditions the study is for
Wolff-Parkinson-White Syndrome
What is being tested?
Electrophysiology testing and exercise stress testing
Type of treatment
Surgery or procedure
How many people
168 participants
Where
1 siteSweden
Study dates
1 Dec 2016to 31 Jan 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All patients with documented ventricular preexcitation, referred for risk assessment to the Arrhythmia department at Karolinska University Hospital, were asked to participate in the study.

Who may be able to join

  • Ventricular pre exciatation on 12 lead ECG

Who cannot join

  • Inability to perform invasive electrophysiology testing or exercise stress test on bicycle.

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Karolinska University Hospital

    Stockholm, SE-14186

Other trials in Sweden

About this study

Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. The purpose of this study is to compare exercise stress testing on bicycle to an invasive electrophysiological study, regarding risk assessment of patients with pre-excitation. The electrophysiology study is set as reference.

Read the detailed description

Hypothesis:

The sensitivity and specificity for exercise stress test (bicycle) is low in identifying patients with benign accessory pathways and cannot replace an invasive electrophysiological study in risk assessment of symptomatic and asymptomatic patients with pre-excitation. Invasive electrophysiological assessment should be recommended for all patients with pre-excitation despite symptoms or documented arrhythmia.

Methods:

Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. The purpose of this study is to compare exercise stress testing on bicycle to an invasive electrophysiological study, regarding risk assessment of patients with pre-excitation. The electrophysiology study is set as reference.

  1. Instruments and methods for analysis:
  • All patients will perform an exercise stress test on a test bike according to standard protocol. ECG will be monitored closely regarding loss of pre-excitation during exercise.
  • After exercise testing all patients will undergo an invasive electrophysiological study according to standard protocol.

This procedure is set as reference in identifying potentially dangerous accessory pathways.

  • APERP as well as shortest R-R interval during atrial fibrillation, when applicable, will be used to characterize the conduction properties of the pathway defining high risk pathway with APERP ≤ 250 ms with or without isoprenaline.
  • Inducibility in AVRT (orthodromic or antidromic reentry tachycardia) and atrial fibrillation will be recorded as well as tachycardia cycle length.
  • The results of the two tests will be compared with each patient being their own control.

Programmed stimulation for risk assessment in patients with pre-excitation/accessory pathways:

  1. AV block or block in AP during IAP, ms
  2. VA block or block in AP during IVP, ms
  3. Antegrade curve (single ES 600 ms or longer and 400 ms): APERP And AVNERP
  4. Retrograde curve (single ES 600 ms): Retrograde APERP and AVNERP
  5. Tachycardia induction (Double ES from atrium): Inducibility
  6. Burst pacing from atrium
  7. Isoprenaline: Dose adjustment until heart rate>100/min or >50% increase from basal level.
  • Antegrade curve during isoprenaline: APERP, AVNERP
  • Retrograde curve during Isoprenaline:

Retrograde APERP and AVNERP

  • Tachycardia induction during Isoprenaline

Statistical analysis: Sensitivity, specificity, positive predictive value and negative predictive value of exercise stress test will be assessed, using the electrophysiological study as a reference standard. A true positive and a false negative will be defined, respectively, as the persistence and the disappearance of pre-excitation in the symptomatic and asymptomatic group. A true negative and a false positive will be defined, respectively, as the disappearance and the persistence of pre-excitation in the symptomatic and asymptomatic group. Moreover, we will consider the shortest value between the minimum RR interval during atrial fibrillation and accessory pathway anterograde effective refractory period (APERP) in each patient and look for the value that could be predicted by noninvasive tests with the best combination of sensitivity, specificity, positive and negative predictive value.

Chi Square statistics will be used in comparing categorical data such as inducibility and tachycardia cycle length.

  1. Calculation of power: With the planned number of patients, 150, a 10% difference should be detected with a power of 80% at α 0,1.
  2. Expected results: We expect exercise testing to have high sensitivity, but low specificity and a low positive predictive value.
Being tested
Electrophysiology testing and exercise stress testing
Keywords
Risk assessment
Medical subject headings
Wolff-Parkinson-White Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Electrophysiology testing and exercise stress testingProcedure or surgery

    Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. RASAP

    Number of potentially dangerous pathways (i.e APERP <250 ms) identified by exercise stress test compared to the invasive electrophysiological test in the symptomatic- and asymptomatic Group.

    Measured: Approximately 1 year from inclusion to 6 months follow-up.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2017
  2. Study start1 Dec 2016
  3. Primary completion31 Jan 2022
  4. Study completion31 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
168 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03301935
Sponsor's protocol ID
RASAP
Acronym
RASAP
Status last verified
May 2022
First submitted
23 Feb 2017
Last updated
24 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Jemtren A, Saygi S, Akerstrom F, Asaad F, Bourke T, Braunschweig F, Carnlof C, Drca N, Insulander P, Kenneback G, Nordin AP, Sadigh B, Rickenlund A, Saluveer O, Schwieler J, Svennberg E, Tapanainen J, Turkmen Y, Bastani H, Jensen-Urstad M. Risk assessment in patients with symptomatic and asymptomatic pre-excitation. Europace. 2024 Feb 1;26(2):euae036. doi: 10.1093/europace/euae036.

    PubMed 38363996

Questions about this trial

What is this clinical trial studying?

An observational study of Wolff-Parkinson-White Syndrome, run by Karolinska University Hospital at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

RASAP (time frame: Approximately 1 year from inclusion to 6 months follow-up.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03301935, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in